Iambic Therapeutics, Inc. (NASDAQ:IAM) Sees Significant Increase in Short Interest

Iambic Therapeutics, Inc. (NASDAQ:IAM – Get Free Report) was the target of a large increase in short interest in October. As of October 30th, there was short interest totaling 1,062,517 shares. Based on an average daily trading volume, of 907,012 shares, the short-interest ratio is presently 1.2 days. Approximately 2.2% of the shares of the stock are short sold.

Iambic Therapeutics Stock Down 9.5%

Shares of NASDAQ IAM traded down $1.25 during mid-day trading on Monday, hitting $11.85. 456,732 shares of the stock were exchanged, compared to its average volume of 757,415. Iambic Therapeutics has a twelve month low of $9.60 and a twelve month high of $25.00.

Iambic Therapeutics (NASDAQ:IAM – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($6.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($5.90). Sell-side analysts expect that Iambic Therapeutics will post -1.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on IAM shares. Zacks Research assumed coverage on Iambic Therapeutics in a research note on Tuesday, November 10th. They set a “hold” rating for the company. Jefferies Financial Group initiated coverage on Iambic Therapeutics in a report on Tuesday, November 10th. They set a “buy” rating and a $35.00 price objective for the company. Wall Street Zen upgraded shares of Iambic Therapeutics to a “hold” rating in a research note on Saturday, November 7th. Citigroup began coverage on shares of Iambic Therapeutics in a report on Monday, November 9th. They issued a “buy” rating and a $22.00 target price on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Iambic Therapeutics in a research report on Monday, November 9th. They set an “overweight” rating and a $22.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $27.25.

Read Our Latest Stock Analysis on IAM

Insider Activity

In related news, Director Evan Lockwood Rachlin bought 718,750 shares of the company’s stock in a transaction dated Friday, October 16th. The stock was acquired at an average cost of $16.00 per share, with a total value of $11,500,000.00. Following the acquisition, the director owned 2,588,248 shares in the company, valued at approximately $41,411,968. This represents a 38.45% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Iambic Therapeutics Company Profile

(Get Free Report)

Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.

See Also

Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.